This inventor holds 1 USPTO granted patent. Top assignees: University of Rijeka Faculty of Medicine, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2020.
Company Filing History:
1 out of 5 
1 out of 911 
Years Active: 2020
Title: Ariella Glasner: Innovator in Autoimmune Disease and Cancer Research
Introduction
Ariella Glasner is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents for autoimmune diseases and cancer. Her innovative work has led to the filing of a patent that showcases her expertise and dedication to advancing medical science.
Latest Patents
Ariella Glasner holds a patent for "Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same." This patent discloses an affinity binding moiety that comprises an antigen recognition region with specific complementarity determining region (CDR) amino acid sequences. The patent outlines a pharmaceutical composition that includes this affinity binding moiety as an active ingredient. Additionally, it describes methods for diagnosing, preventing, or treating autoimmune diseases or cancers associated with the expression of NKp46. This innovative approach has the potential to significantly impact therapeutic strategies in these areas.
Career Highlights
Throughout her career, Ariella has worked with esteemed institutions, including Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and the University of Rijeka Faculty of Medicine. Her work in these organizations has allowed her to collaborate with leading researchers and contribute to groundbreaking studies in her field.
Collaborations
Ariella Glasner has collaborated with notable colleagues, including Ofer Mandelboim and Stipan Jonjic. These partnerships have enriched her research and expanded the impact of her innovations in the scientific community.
Conclusion
Ariella Glasner is a trailblazer in the realm of autoimmune disease and cancer research. Her patent and collaborative efforts reflect her commitment to advancing medical science and improving patient outcomes. Her contributions are a testament to the importance of innovation in healthcare.